

Diffuse Large B-Cell Lymphoma (DLBCL)

A clinical trial to compare glofitamab plus Pola-R-CHP with Pola-R-CHP alone in people with untreated large B-cell lymphoma

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Trial Status
Recruiting

Trial Runs In
21 Countries

Trial Identifier
NCT06047080 GO44145

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Official Title:

A phase III, multicenter, randomized, open-label trial comparing the efficacy and safety of glofitamab (RO7082859) in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus Pola-R-CHP in previously untreated patients with large B-cell lymphoma

Trial Summary:

The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT06047080 GO44145
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
#18 Years & # 80 Years

Healthy Volunteers
No

1. Why is the GO44145 clinical trial needed?

Large B-cell lymphoma (LBCL) is the most common type of non-Hodgkin lymphoma. Lymphoma is a type of cancer that starts in white blood cells called lymphocytes. Lymphocytes help protect the body from infection but in LBCL, B-cell lymphocytes become abnormal and collect in the lymph nodes and spleen. This causes lymph nodes to swell and form cancerous tumours. The standard first treatment for LBCL is a combination of chemotherapy and immunotherapy. Immunotherapies are medicines that help the body to use its immune system to fight the cancer. Pola-R-CHP is a standard first treatment that combines polatuzumab vedotin (pola) plus rituximab (R), cyclophosphamide (C), doxorubicin (H), and prednisone (P). For some people, their cancer does not respond to treatment, or it comes back after their first treatment. Glofitamab is an experimental drug that attaches to a protein called CD20 that is found on some types of LBCL cells. It can join to another protein on cancer-killing cells of the immune system. This brings them closer together so immune cells destroy the LBCL cells. Glofitamab plus Pola-R-CHP may work better as a first treatment than Pola-R-CHP alone for LBCL that has CD20. This clinical trial aims to compare the effects, good or bad, of glofitamab plus Pola-R-CHP versus Pola-R-CHP alone in people with LBCL.

2. How does the GO44145 clinical trial work?

This clinical trial is recruiting people with a health condition called LBCL. People can take part if they have untreated CD20-positive LBCL. People who take part in this clinical trial (participants) will be given the clinical trial treatment glofitamab plus Pola-R-CHP or Pola-R-CHP alone. Treatment will last for about 6 months (24 weeks). The clinical trial treatment is given in eight 21-day 'cycles'; a cycle is the treatment and recovery time. To reduce the chance of side effects from glofitamab treatment, participants will build up to the intended target dose (called 'step-up' doses). The clinical trial doctor will see participants while treatment is being given and about one month after the last dose of treatment. Hospital visits will include checks to see how the participant responds to the treatment and any side effects they may have. The clinical trial doctor will then follow up with participants about every 3 months by telephone for as long as agreed to. There will be ongoing long-term follow up which will include scans, telephone calls, and questionnaires. The total time in the clinical trial will be approximately 3 years. Participants can stop trial treatment and leave the clinical trial at any time.

3. What are the main endpoints of the GO44145 clinical trial?

The main clinical trial endpoint (the main result measured in the trial to see if the drug has worked) is the length of time between the start of the trial and a participant's cancer getting worse, if applicable (known as 'progression-free survival', or PFS).

The other clinical trial endpoints include:

- The time between starting the trial and having a change in disease or treatment (event-free survival)

ForPatients

by Roche

- How many participants have no signs of cancer (complete response rate)
- How many participants have a smaller tumour size after treatment (objective response rate)
- How long participants live after treatment (overall survival)
- The time between participants' cancer getting better from treatment and then getting worse (duration of response) or having no signs of cancer and then cancer getting worse (duration of complete response)
- The number and seriousness of any side effects
- How the body processes the clinical trial treatment
- The number of participants who have positive or negative effects of treatment on their health

4. Who can take part in this clinical trial?

People can take part in this trial if they are aged 18 to 80 and have LBCL with the CD20 marker. Participants must also have an IPI score of 2–5. This is a scale of 1–5 which aids in predicting the prognosis of patients. Participants need to be willing to allow a sample of their tumour to be checked for CD20.

People may not be able to take part in this trial if they:

- Have received previous treatment for LBCL (except steroids for symptom control)
- Have had treatment for any condition with immunotherapy medicine shortly before the trial
- Have or had medical conditions including lymphoma and viral infections (such as HIV, hepatitis B or C, cancers, heart disease or liver disease, organ transplant or recent major surgery)
- Are pregnant or breastfeeding, or are planning to become pregnant during the trial

5. What treatment will participants be given in this clinical trial?

Everyone who joins this clinical trial will be split into 2 groups randomly (like flipping a coin) and given either:

Group A: Glofitamab and Pola-R-CHP

- Glofitamab will be given in two increasing doses as an infusion (into the vein) in Cycles 2–8
- Pola, -R, -C, and H from pola-R-CHP will be given as an infusion (into the vein) in Cycles 1–6

Group B: Pola-R-CHP alone

- Pola, -R, -C, and H from pola-R-CHP will be given as an infusion (into the vein) in Cycles 1–6

- Rituximab (part of Pola-R-CHP) only will be given in Cycles 7 and 8 as an infusion (into the vein)

In both groups, prednisone (P) will be given as a pill (to be swallowed), or may be replaced with prednisolone (given as a pill), or with methylprednisolone (given as an infusion) . If a participant experiences a potential side effect called 'cytokine release syndrome' (inflammatory throughout the body), they may receive another medicine called tocilizumab. This is an open-label trial, which means everyone involved, including the participant and the clinical trial doctor, will know the clinical trial treatment the participant has been given.

6. Are there any risks or benefits in taking part in this clinical trial?

The safety or effectiveness of the experimental treatment or use may not be fully known at the time of the trial. Most trials involve some risks to the participant. However, it may not be greater than the risks related to routine medical care or the natural progression of the health condition. People who would like to participate will be told about any risks and benefits of taking part in the clinical trial, as well as any additional procedures, tests, or assessments they will be asked to undergo. All of these will be described in an informed consent document (a document that provides people with the information they need to decide to volunteer for the clinical trial).

Risks associated with the clinical trial drugs

Participants may have side effects (an unwanted effect of a drug or medical treatment) from the drugs used in this clinical trial. Side effects can be mild to severe, even life-threatening, and vary from person to person. Participants will be closely monitored during the clinical trial; safety assessments will be performed regularly. Participants will be told about the known side effects of **glofitamab, polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, prednisone/prednisolone/methylprednisolone** and **tocilizumab** and possible side effects based on human and laboratory studies or knowledge of similar drugs. **Glofitamab, polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, methylprednisolone** and **tocilizumab** will be given by infusion (into the vein). Participants will be told about any known side effects of infusion or . **Prednisone/prednisolone** will be given as a pill (to be swallowed). Participants will be told about any known side effects of swallowing pills.

Potential benefits associated with the clinical trial

Participants' health may or may not improve from participation in the clinical trial. Still, the information collected may help other people with similar medical conditions in the future.

Inclusion Criteria:

- Previously untreated participants with CD20-positive LBCL

ForPatients

by Roche

- Ability to provide tumor tissue
- International prognostic index (IPI) score 2-5
- Eastern cooperative oncology group (ECOG) performance status of 0, 1, or 2
- At least one bi-dimensionally measurable lesion, defined as > 1.5 cm in its longest dimension as measured by CT or MRI
- Left ventricular ejection fraction (LVEF) $\geq 50\%$ on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO)
- Adequate hematologic function
- Negative HIV test at screening with exceptions as defined by the protocol
- Negative SARS-CoV-2 antigen or PCR test

Exclusion Criteria:

- Contraindication to any of the individual components of Pola-R-CHP or glofitamab, including prior receipt of anthracyclines, or history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies, or known sensitivity or allergy to murine products
- Prior solid organ transplantation
- Participants receiving systemic immunosuppressive agent such as, but not limited to cyclosporin, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 4 weeks prior to first dose of study treatment
- Current Grade > 1 peripheral neuropathy by clinical examination or demyelinating form of Charcot-Marie-Tooth disease
- History of indolent lymphoma (e.g., Follicular Lymphoma, Marginal Zone Lymphoma, Waldenstrom macroglobulinemia)
- Current diagnosis of the following: Follicular lymphoma grade 3B; transformations of indolent B-cell lymphomas (e.g., de novo transformed follicular lymphoma); mediastinal grey zone lymphoma; primary mediastinal (thymic) large B-cell lymphoma; Burkitt lymphoma; primary large B-cell lymphoma of immune-privileged sites (encompassing primary diffuse large B-cell lymphoma of the CNS, primary large B-cell lymphoma of the vitreoretina and primary large B-cell lymphoma of the testis); primary effusion DLBCL; and primary cutaneous DLBCL, leg type
- Primary or secondary CNS lymphoma at the time of recruitment or history of CNS lymphoma
- Prior treatment with systemic immunotherapeutic agents
- Prior use of any monoclonal antibody for the purposes of treating cancer within 3 months of the start of Cycle 1
- Any investigational therapy for the purposes of treating cancer within 28 days prior to the start of Cycle 1
- Prior radiotherapy to the mediastinal/pericardial region
- Prior therapy for LBCL, with the exception of corticosteroids
- Corticosteroid use > 30 mg/day of prednisone or equivalent, for purposes other than lymphoma symptom control
- History of other malignant or non-malignant diseases that could affect compliance with the protocol or interpretation of results
- Significant or extensive history of cardiovascular disease
- Recent major surgery (within 4 weeks prior to the start of Cycle 1), other than for diagnosis
- Current or past history of central nervous system (CNS) disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
- Known or suspected chronic active Epstein-Barr viral infection
- Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
- Active autoimmune disease requiring treatment
- Clinically significant liver disease

ForPatients

by Roche

- Live, attenuated vaccine within 4 weeks before study treatment infusion on Day 1 of Cycle 1 or anticipation that such a live, attenuated vaccine will be required during the study. Live vaccines during the study and until participants B cells recover are prohibited
- Any active infection within 7 days prior to Cycle 1 Day 1 that would impact participant safety
- Suspected active or latent tuberculosis
- Positive test results for chronic hepatitis B infection, hepatitis C, or the human T-lymphotropic virus type 1 (HTLV-1)
- History of progressive multifocal leukoencephalopathy